Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size

European Urology

Volumn 55, Issue 2, 2009, Pages 472-481

  Roehrborn, Claus G ^a   Kaplan, Steven A ^b   Jones, J Stephen ^c   Wang, Joseph T ^d   Bavendam, Tamara ^d   Guan, Zhonghong ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d PFIZER INC   (United States)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Overactive bladder; Prostate volume; Quality of life; Tamsulosin; Tolterodine extended release

Indexed keywords

PLACEBO; TAMSULOSIN; TOLTERODINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; URINE FLOW RATE; URINE INCONTINENCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DIURESIS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MUSCARINIC AGONISTS; ORGAN SIZE; PHENYLPROPANOLAMINE; PROSTATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; URINARY BLADDER, OVERACTIVE; URINARY RETENTION;

EID: 57649158625     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.032     Document Type: Article

References (29)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003) 37-49
2. Chapple C.R., and Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49 (2006) 651-659
3. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
4. Boyle P., Robertson C., Mazzetta C., et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 92 (2003) 409-414
5. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1315
6. Abdel-Aziz K.F., and Lemack G.E. Overactive bladder in the male patient: bladder, outlet, or both?. Curr Urol Rep 3 (2002) 445-451
7. de Nunzio C., Franco G., Rocchegiani A., et al. The evolution of detrusor overactivity after watchful waiting, medical therapy, and surgery in patients with bladder outlet obstruction. J Urol 169 (2003) 535-539
8. Laniado M.E., Ockrim J.L., Marronaro A., Tubaro A., and Carter S.S. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 94 (2004) 1283-1286
9. Hyman M.J., Groutz A., and Blaivas J.G. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166 (2001) 550-552
10. Andersson K.E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3 (2004) 46-53
11. Blake-James B.T., Rashidian A., Ikeda Y., and Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99 (2007) 85-96
12. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 (2005) 2273-2276
13. Kaplan S.A., Roehrborn C.G., Dmochowski R., et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68 (2006) 328-332
14. Roehrborn C.G., Abrams P., Rovner E.S., et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 97 (2006) 1003-1006
15. Abrams P., Kaplan S.A., De Koning Gans H.J., and Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 (2006) 999-1004
16. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319-2328
17. Kaplan S.A., McConnell J.D., Roehrborn C.G., et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175 (2006) 217-220
18. Coyne K.S., Matza L.S., Kopp Z., and Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49 (2006) 1079-1086
19. Coyne K., Tubaro A., Brubaker L., and Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder. Urology 68 Suppl 2A (2006) 9-16
20. Coyne KS, Matza L, Thompson C, Bavendam T, Jumadilova Z. A comparison of three approaches to analyze urinary urgency as a treatment outcome. Paper presented at: 35th Annual Meeting of the International Continence Society; August 28-September 2, 2005; Montreal, Quebec, Canada.
21. Ruggieri Sr. M.R., Braverman A.S., and Pontari M.A. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 174 (2005) 1743-1748
22. Athanasopoulos A., Gyftopoulos K., Giannitsas K., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169 (2003) 2253-2256
23. Yang Y., Zhao X.F., Li H.Z., et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 120 (2007) 370-374
24. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. The effect of serum prostate-specific antigen level on the efficacy of tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder. Urology. In press.
25. Roehrborn C.G., Boyle P., Gould A.L., and Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581-589
26. Peters T.J., Donovan J.L., Kay H.E., et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms. J Urol 157 (1997) 885-889
27. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
28. Szell E.A., Yamamoto T., de Groat W.C., and Somogyi G.T. Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol 130 (2000) 1685-1691
29. Casado M.A., Sevilla M.A., Alonso M.J., Marin J., and Salaices M. Muscarinic receptors involved in modulation of norepinephrine release and vasodilatation in guinea pig carotid arteries. J Pharmacol Exp Ther 271 (1994) 1638-1646